- Home
- OKTA vs NBIX Comparison
OKTA vs NBIX Comparison
Compare OKTA & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OKTA | NBIX |
|---|---|---|
| Founded | 2009 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0B | 13.9B |
| IPO Year | 2017 | 1996 |
Fundamental Metrics
Financial Performance| Metric | OKTA | NBIX |
|---|---|---|
| Price | $85.31 | $124.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 37 | 20 |
| Target Price | $116.86 | ★ $177.50 |
| AVG Volume (30 Days) | ★ 2.6M | 1.2M |
| Earning Date | 03-04-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | 1.08 | ★ 4.67 |
| Revenue | $2,840,000,000.00 | ★ $2,860,500,000.00 |
| Revenue This Year | $13.64 | $21.24 |
| Revenue Next Year | $9.10 | $8.59 |
| P/E Ratio | $78.98 | ★ $26.36 |
| Revenue Growth | 12.12 | ★ 21.45 |
| 52 Week Low | $75.05 | $84.23 |
| 52 Week High | $127.57 | $160.18 |
Technical Indicators
Market Signals| Indicator | OKTA | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 32.50 |
| Support Level | $83.36 | $122.14 |
| Resistance Level | $89.79 | $142.82 |
| Average True Range (ATR) | 3.57 | 4.41 |
| MACD | -0.13 | -0.94 |
| Stochastic Oscillator | 44.09 | 13.41 |
Price Performance
Historical ComparisonAbout OKTA Okta Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.